Drugs / ChAdOx1 nCoV-19 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05133609 | Jan 2021 → Aug 2022 | COVID-19 | Federal University of Espirito Santo | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04730895 Comparator | Jul → Sep 2021 | — | Kafrelsheikh University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-07-23 | AstraZeneca | Results Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern astrazeneca.com ↗
The vaccine also showed a high level of effectiveness against the Delta (B.617.2, ‘Indian’) and Alpha (B.1.1.7, ‘Kent’) variants with an 87% and 90% reduction of hospitalisations or deaths respectively. |
| 2021-05-21 | AstraZeneca | Regulatory AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan astrazeneca.com ↗
AstraZeneca’s COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) , formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-07-23 | AstraZeneca | Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern astrazeneca.com ↗ |
| 2021-05-21 | AstraZeneca | AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan astrazeneca.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 nCoV-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05133609 ↗ |
| Known as | AZD1222 | “ChAdOx1 nCoV-19 vaccine (AZD1222)” NCT05133609 ↗ |
| Modality | Vaccine | “spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine” NCT04730895 ↗ |